News & Updates

Show Multimedia Only

Statins may protect adults with T1DM against all-cause death, CVD

19 Sep 2025

The use of statins for primary prevention in adults with type 1 diabetes mellitus (T1DM) appears to prevent all-cause mortality and major cardiovascular disease (CVD), with an acceptable safety profile, a study has shown.

Statins may protect adults with T1DM against all-cause death, CVD

19 Sep 2025

Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk

19 Sep 2025 by

Treatment with inclisiran, on top of individually optimized lipid-lowering therapy (ioLLT), resulted in the achievement of guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets among patients with hypercholesterolaemia at high or very high risk of cardiovascular (CV) events, according to the VICTORION-Difference trial presented at ESC 2025.

Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk

19 Sep 2025

Vaginal estrogen tablets unlikely to increase risk of stroke recurrence

18 Sep 2025 by

Among women who have previously had an ischaemic stroke, the use of vaginal estradiol tablets does not raise the risk of having another stroke, according to new research.

Vaginal estrogen tablets unlikely to increase risk of stroke recurrence

18 Sep 2025

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

18 Sep 2025 by

Many patients with cirrhosis and acute kidney injury (AKI) need 2 days to show response to albumin treatment, a study has found. Therefore, reducing the duration of albumin therapy may result in overtreatment with terlipressin.

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

18 Sep 2025

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

18 Sep 2025

The addition of pembrolizumab to the combination of gemcitabine and cisplatin does not appear to worsen the health-related quality of life (HRQoL) in patients with advanced biliary tract cancer (BTC), results of the phase III KEYNOTE-966 study have shown.

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

18 Sep 2025

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

17 Sep 2025 by

Patients with heart failure (HF) with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes (T2D) show a favourable response to tirzepatide despite less pronounced weight loss, reports a study.

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

17 Sep 2025

Long-term denosumab viable in patients with rheumatic diseases

17 Sep 2025

The use of denosumab for longer durations is generally safe and effective for increasing bone mineral density (BMD) in patients with rheumatic diseases (RDs), suggests a recent study.

Long-term denosumab viable in patients with rheumatic diseases

17 Sep 2025

Admilparant shows promise in idiopathic, progressive pulmonary fibrosis

17 Sep 2025

The investigational oral lysophosphatidic acid receptor 1 antagonist admilparant helps delay disease progression in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis, according to a phase II trial.

Admilparant shows promise in idiopathic, progressive pulmonary fibrosis

17 Sep 2025

Myo-inositol supplementation of no help in pregnant women with PCOS

16 Sep 2025

Daily myo-inositol supplementation does not appear to reduce the risk of pregnancy complications such as gestational diabetes, preterm birth, and pre-eclampsia in women with polycystic ovary syndrome (PCOS), according to a study.

Myo-inositol supplementation of no help in pregnant women with PCOS

16 Sep 2025

Inactive disease a viable target in tofacitinib-treated patients with JIA

16 Sep 2025 by

Treatment with tofacitinib improves the rates of Juvenile Arthritis Disease Activity Score (JADAS) in 10 joints (JADAS10)-clinically inactive disease (CID) and American College of Rheumatology (ACR)-CID in patients with juvenile idiopathic arthritis (JIA), with improvements sustained over time, a study has shown. Additionally, a few patients have achieved JADAS10 remission.

Inactive disease a viable target in tofacitinib-treated patients with JIA

16 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Statins may protect adults with T1DM against all-cause death, CVD

Statins may protect adults with T1DM against all-cause death, CVD

Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk

Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk

Vaginal estrogen tablets unlikely to increase risk of stroke recurrence

Vaginal estrogen tablets unlikely to increase risk of stroke recurrence

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

Long-term denosumab viable in patients with rheumatic diseases

Long-term denosumab viable in patients with rheumatic diseases

Admilparant shows promise in idiopathic, progressive pulmonary fibrosis

Admilparant shows promise in idiopathic, progressive pulmonary fibrosis

Myo-inositol supplementation of no help in pregnant women with PCOS

Myo-inositol supplementation of no help in pregnant women with PCOS

Inactive disease a viable target in tofacitinib-treated patients with JIA

Inactive disease a viable target in tofacitinib-treated patients with JIA